An Increasingly Global Approach: January 2016 Therapeutic Innovation & Regulatory Science

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma in patients over 12 years of age.

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.

The collaboration will launch four development programs targeting key G protein-coupled receptors—GLP-1, GIP, and glucagon—to develop oral cardiometabolic medicines.

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.

The organization believes that the proposed cuts will be harmful to Americans suffering from mental illnesses.

The protection and privacy of healthcare data is a massive hurdle for the new technology to overcome.